IGF-1 LR3
Long-acting Insulin-like Growth Factor 1 analog. Extended half-life vs native IGF-1. Used for muscle growth, recovery, and hyperplasia.
Overview
Long-acting Insulin-like Growth Factor 1 analog. Extended half-life vs native IGF-1. Used for muscle growth, recovery, and hyperplasia.
Can cause hypoglycaemia (insulin-like effects on glucose uptake), significantly elevates IGF-1 levels, may worsen insulin sensitivity with prolonged use, can promote gut growth at high doses, does not directly affect liver enzymes or lipids
Compound Guide
Structure: Recombinant IGF-1 with an arginine substitution at position 3 and a 13-amino-acid extension at the N-terminus. These modifications reduce IGF binding protein affinity, dramatically increasing half-life and bioavailability.
Dosage:
- Standard: 20-50mcg/day, post-workout
- Advanced: 50-100mcg/day split into bilaterally injected muscle groups
- Localised growth: 20-40mcg injected into target muscle immediately post-training
Administration:
- SubQ or intramuscular (IM into trained muscle for localised effect)
- 27-30g insulin syringe
- Post-workout timing preferred — muscles are insulin-sensitive
Key Notes:
- Promotes both muscle hypertrophy and hyperplasia (new muscle cell formation — unlike AAS which only cause hypertrophy)
- Hypoglycaemia risk is real — have fast-acting carbs available, eat within 30 min of injection
- Extended use can worsen insulin sensitivity — cycle 4-6 weeks on, 4 weeks off
- High doses promote visceral organ growth (gut, heart) — keep doses moderate
- Monitor: fasting glucose, HbA1c, IGF-1 levels
- Does not require GH to be effective (unlike endogenous IGF-1 which is GH-dependent)
- Reconstitute with bacteriostatic water or acetic acid solution, store refrigerated, use within 30 days
Usage History
Frequently Asked Questions
Quick Reference
Category
Peptide
Half-Life
20-30 hours
Detection Time
N/A